BC
CAMP icon

Birchview Capital’s CAMP4 Therapeutics CAMP Stock Holding History

Birchview Capital’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524K Buy
+120,000
New +$517K 0.25% 51

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Birchview Capital's CAMP Position: Q2 2026 in Review

Birchview Capital opened a new position in CAMP4 Therapeutics (CAMP) in Q2 2026: 120,000 shares worth $524K. The stake represents 0.25% of the portfolio and ranks #51 among its holdings.

61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Birchview Capital held 120,000 shares of CAMP4 Therapeutics worth $524K as of Q2 2026.
  • CAMP4 Therapeutics was a new Birchview Capital position in Q2 2026.
  • CAMP4 Therapeutics made up 0.25% of Birchview Capital's portfolio in Q2 2026, its #51 holding.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.